News
-
-
PRESS RELEASE
aap 100% approval of the proposed resolution to amend the terms and conditions of the mandatory convertible bond 2023/2028
aap Implantate AG receives 100% approval to amend terms of mandatory convertible bond 2023/2028. Bondholders granted early conversion option without lock-up period. Strong support from creditors -
-
PRESS RELEASE
EQS-Adhoc: aap Implantate AG: Capital increase from authorized capital with exclusion of subscription rights
aap Implantate AG announces capital increase of EUR 896,647.00 through private placement for strengthening equity base. Share capital to increase to EUR 9,863,121.00 with issue price per share of EUR 1.10 -
-
PRESS RELEASE
EQS-Adhoc: aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier
aap Implantate AG proposes an amendment to the bond terms and conditions of the mandatory convertible bond 2023/2028 to allow earlier exercise of conversion rights by bondholders -
PRESS RELEASE
After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
aap Implantate AG accelerates patient recruitment for antibacterial implant technology study, reports strong sales start in 2024, initiates MDR certification, and plans for third-party funding. Mixed 2023, positive 2024 outlook -
-
-